Was my baby at risk from penicillamine if I was on it while pregnant?

The anxiety behind this question is completely understandable. You have taken a powerful drug for two decades and then became pregnant — of course you want to know what that meant for your child. Here is the honest answer: penicillamine does carry a teratogenic risk, meaning it can interfere with fetal development, and that risk is real and documented. But it is not a certainty, it is not a death sentence for a pregnancy, and the medical evidence — built over many years of managing Wilson disease in pregnant women — gives a more nuanced and ultimately more reassuring picture than a worst-case reading of the drug label would suggest.¹

What penicillamine can do to a developing baby

Penicillamine works by binding copper and helping the body excrete it, but it also affects connective tissue formation. This is the same mechanism that causes skin changes in some long-term users — and it is also the mechanism that poses fetal risk. Specifically, penicillamine can interfere with collagen cross-linking in fetal tissues, and a small number of cases have been reported in which infants born to mothers on penicillamine showed connective-tissue abnormalities — loose, fragile skin (cutis laxa), joint hypermobility, or abnormal skin fragility.²

The first reported case, published in 1971, described a baby born with a generalised connective-tissue defect after the mother took penicillamine throughout pregnancy for Wilson disease.² Subsequent case reports followed. These cases are rare, but they established that the drug is not completely safe in pregnancy — which is why penicillamine is the medication that clinicians most actively try to modify or switch during pregnancy, when possible.

What the larger cohort evidence shows

Individual case reports tell you what can happen; larger datasets tell you what typically happens. Two studies provide the most useful numbers.

The German Embryotox database analysis by Dathe and colleagues looked at pregnancy outcomes in women who took chelating agents (primarily penicillamine and trientine) during pregnancy.³ The majority of pregnancies in women on controlled therapy resulted in healthy infants. The authors noted that untreated Wilson disease during pregnancy carries its own serious risks — hepatic decompensation, miscarriage, premature birth — which means stopping medication entirely is not a safe alternative.³

The large European multicentre cohort study by Pfeiffenberger and colleagues (2018) examined 282 pregnancies in 136 women with Wilson disease over several decades.¹ The overall picture was that women who maintained treatment throughout pregnancy — whether with penicillamine, trientine, or zinc — had much better maternal and fetal outcomes than those who did not. Adverse outcomes were more common in untreated pregnancies. Structural fetal abnormalities attributable to the medication were not common in this cohort.¹

A smaller experience from a German perinatal centre, reported by Reuner and colleagues, added further evidence that careful management — with dose reduction where possible and close monitoring — generally results in good outcomes.⁴

Does 20 years on penicillamine change the picture?

The short answer is: not materially. The fetal risk from penicillamine relates to what the drug does to fetal tissue during pregnancy, not to how long the mother has been taking it before conception. Long-term maternal use before pregnancy does not accumulate teratogenic damage in the mother that then transfers to the fetus. The relevant question is: what dose was taken, and when, during the pregnancy itself?

However, 20 years of penicillamine does matter in one important respect: your body and your disease will have adapted to it, and your clinical team will have a long track record of your copper studies. That history is actually useful — it means your team can look back at your urine copper levels over years, assess whether your disease is well-controlled, and evaluate whether the drug is working at the lowest effective dose. Well-controlled copper on a stable, possibly reduced dose carries lower risk than poorly controlled disease.⁵

What specialists recommend during pregnancy

Current guidance, including both the AASLD 2022 Practice Guidance and the EASL guidelines, recommends that women with Wilson disease do not stop treatment during pregnancy — because uncontrolled copper accumulation during pregnancy is dangerous for both mother and baby.⁵⁶ Instead, the approach is:

• Dose reduction, where possible: some specialists aim to reduce penicillamine to the lowest dose that maintains copper control during pregnancy, particularly in the first trimester when organogenesis is happening.
• Switching to an alternative: trientine is generally considered to carry lower teratogenic risk than penicillamine, and zinc is sometimes considered for maintenance in women who are well-controlled before conception. Switching should be done before or very early in pregnancy, not during.
• Close monitoring: regular copper studies (urine copper, serum ceruloplasmin), liver function tests, and fetal ultrasound.

If you remained on penicillamine throughout pregnancy because stopping or switching was not feasible or recommended by your team at the time, you were following the principle that untreated disease is more dangerous than treated disease. This is the position reflected in all the major evidence reviewed above.

What to discuss with your team now

If your baby is already born and you are looking backward at this question, there are a few practical points:

• Your baby’s paediatrician should be aware of penicillamine exposure in utero. Most exposed infants are normal at birth and have normal development. The connective-tissue effects described in case reports were apparent at birth; they are not something that emerges years later.
• If any of the described skin or joint findings were noted at your baby’s newborn check, they should already be in the record. If the paediatrician found nothing concerning, that is meaningful reassurance.
• Wilson disease is autosomal recessive — your child cannot develop Wilson disease unless they inherited one ATP7B variant from each parent. If you are not sure about your partner’s carrier status, the family-screening page explains how carrier testing works and when it matters.

For the broader topic of managing Wilson disease through pregnancy — including medication choices, trimester-by-trimester monitoring, and what to tell your obstetric team — the dedicated pregnancy page covers this in full.

The honest bottom line

Penicillamine carries a real teratogenic risk, and that risk has been known for more than 50 years. But it is a risk that manifests in a minority of exposed pregnancies, and the evidence from large cohort studies shows that most women who manage Wilson disease carefully through pregnancy — with treatment maintained at controlled doses — deliver healthy children.¹³ The decision not to stop treatment is based on evidence that untreated disease is more dangerous than the medication. That calculation does not guarantee a perfect outcome, but it represents the best available guidance. If your child was born healthy, that is a genuinely good outcome, not a statistical accident.

This page is patient education. It is not a substitute for a conversation with your hepatologist, obstetrician, and your child’s paediatrician, who know your specific history and can advise you directly.

References